ARPO - Aerpio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aerpio Pharmaceuticals, Inc.

9987 Carver Road
Suite 420
Cincinnati, OH 45242
United States
513-985-1920
http://www.aerpio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Dr. Joseph H. GardnerFounder, Pres, Principal Exec. Officer & Director620.57kN/A1956
Ms. Regina MarekPrincipal Financial Officer, Principal Accounting Officer & VP of Fin.316.72kN/A1969
Mr. Kevin G. PetersChief Scientific Officer & Acting Chief Medical Officer497.87kN/A1957
Dr. Dhaval DesaiChief Strategy OfficerN/AN/A1978
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.

Corporate Governance

Aerpio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.